COMP <GO>
BAX vs GMED // RETURN ON INVESTED CAPITAL (ROIC)
Baxter International Inc. (NYSE) VS. Globus Medical Inc. (NYSE) • 15-METRIC TALLY: BAX 2
— GMED 11
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: GMED
LAST: $23.50 (-7.70%) • MKT CAP: $12.15B
roic
-2.40%
LAST: $82.91 (+2.03%) • MKT CAP: $11.13B
roic
8.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BAX VS. GMED)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BAX | GMED | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 30.10% | 67.40% | -37.30 | GMED | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -2.40% | 8.70% | -11.10 | GMED | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 17.6x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.79% | 5.29% | -2.50 | GMED | /fcf-yield <GO> |
| Operating Margin | -2.70% | 16.30% | -19.00 | GMED | /operating-margins <GO> |
| Net Profit Margin | -8.50% | 18.30% | -26.80 | GMED | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 16.70% | -11.00 | GMED | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.86% | 0.00% | +2.86 | BAX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.22 | 10.74 | -8.52 | GMED | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | GMED | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.3 | 59.8 | -17.50 | GMED | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.07 | -0.12 | GMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 17.4x | +0.60 | GMED | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.15B | $11.13B | $1.02B | BAX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BAX REV | GMED REV | BAX GROSS % | GMED GROSS % | BAX FCF | GMED FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.24B | $2.94B | 30.1% | 67.4% | $339.0M | $588.8M |
| FY 2024 | $10.64B | $2.52B | 37.5% | 58.9% | $540.4M | $405.2M |
| FY 2023 | $10.36B | $1.57B | — | — | $1.26B | $172.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BAX // BETA 0.95
GMED // BETA 1.07